Back to search
Refractory/Relapsed B-cell Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Refractory/Relapsed B-cell Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Refractory/Relapsed B-cell Lymphoma trials you may qualify forBackground: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a…
This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse lar…
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with ot…
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) ch…
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with…
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-r…
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressi…
This phase I trial studies the side effects and best dose of lenalidomide and ibrutinib in treating patients with B-cell non-Hodgkin lymphoma that has returned…